Skip to content 
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. more
| Time Frame | AMPH | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -6.02% | -1.66% | -0.96% |
| 1-Month Return | -36.23% | -4.76% | -2.3% |
| 3-Month Return | -30.92% | -3.81% | -2.15% |
| 6-Month Return | -33.35% | 9.66% | 0.81% |
| 1-Year Return | -30.74% | 4.4% | 20.8% |
| 3-Year Return | -49.1% | 19.83% | 72.98% |
| 5-Year Return | -5.09% | 30.13% | 68.06% |
| 10-Year Return | 55.21% | 119.85% | 229.83% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 437.77M | 498.99M | 644.39M | 731.97M | 719.89M | [{"date":"2021-12-31","value":59.81,"profit":true},{"date":"2022-12-31","value":68.17,"profit":true},{"date":"2023-12-31","value":88.04,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":98.35,"profit":true}] |
| Cost of Revenue | 238.03M | 250.13M | 293.27M | 358.11M | 363.83M | [{"date":"2021-12-31","value":65.42,"profit":true},{"date":"2022-12-31","value":68.75,"profit":true},{"date":"2023-12-31","value":80.61,"profit":true},{"date":"2024-12-31","value":98.43,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | 199.74M | 248.86M | 351.12M | 373.86M | 356.06M | [{"date":"2021-12-31","value":53.43,"profit":true},{"date":"2022-12-31","value":66.57,"profit":true},{"date":"2023-12-31","value":93.92,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":95.24,"profit":true}] |
| Gross Margin | 45.63% | 49.87% | 54.49% | 51.08% | 49.46% | [{"date":"2021-12-31","value":83.74,"profit":true},{"date":"2022-12-31","value":91.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":93.74,"profit":true},{"date":"2025-12-31","value":90.77,"profit":true}] |
| Operating Expenses | 129.85M | 141.36M | 154.13M | 168.44M | 215.65M | [{"date":"2021-12-31","value":60.21,"profit":true},{"date":"2022-12-31","value":65.55,"profit":true},{"date":"2023-12-31","value":71.47,"profit":true},{"date":"2024-12-31","value":78.1,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Income | 69.89M | 107.50M | 196.99M | 205.42M | 140.40M | [{"date":"2021-12-31","value":34.02,"profit":true},{"date":"2022-12-31","value":52.33,"profit":true},{"date":"2023-12-31","value":95.9,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":68.35,"profit":true}] |
| Total Non-Operating Income/Expense | 13.76M | 6.84M | (42.10M) | (35.96M) | (33.58M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":49.72,"profit":true},{"date":"2023-12-31","value":-305.98,"profit":false},{"date":"2024-12-31","value":-261.33,"profit":false},{"date":"2025-12-31","value":-244.05,"profit":false}] |
| Pre-Tax Income | 83.93M | 114.86M | 169.38M | 189.19M | 123.62M | [{"date":"2021-12-31","value":44.36,"profit":true},{"date":"2022-12-31","value":60.71,"profit":true},{"date":"2023-12-31","value":89.53,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":65.34,"profit":true}] |
| Income Taxes | 20.63M | 23.48M | 31.83M | 29.67M | 25.53M | [{"date":"2021-12-31","value":64.81,"profit":true},{"date":"2022-12-31","value":73.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":93.21,"profit":true},{"date":"2025-12-31","value":80.2,"profit":true}] |
| Income After Taxes | 63.30M | 91.39M | 137.54M | 159.52M | 98.09M | [{"date":"2021-12-31","value":39.68,"profit":true},{"date":"2022-12-31","value":57.29,"profit":true},{"date":"2023-12-31","value":86.22,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":61.49,"profit":true}] |
| Income From Continuous Operations | 63.51M | 91.39M | 135.29M | 159.52M | 98.09M | [{"date":"2021-12-31","value":39.81,"profit":true},{"date":"2022-12-31","value":57.29,"profit":true},{"date":"2023-12-31","value":84.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":61.49,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 62.12M | 91.39M | 137.54M | 159.52M | 98.09M | [{"date":"2021-12-31","value":38.94,"profit":true},{"date":"2022-12-31","value":57.29,"profit":true},{"date":"2023-12-31","value":86.22,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":61.49,"profit":true}] |
| EPS (Diluted) | 1.36 | 1.97 | 3.30 | 3.86 | 3.25 | [{"date":"2021-12-31","value":35.23,"profit":true},{"date":"2022-12-31","value":51.04,"profit":true},{"date":"2023-12-31","value":85.49,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":84.2,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| AMPH | |
|---|---|
| Cash Ratio | 1.79 |
| Current Ratio | 4.02 |
| Quick Ratio | 2.90 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| AMPH | |
|---|---|
| ROA (LTM) | 6.37% |
| ROE (LTM) | 12.90% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| AMPH | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.52 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.48 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| AMPH | |
|---|---|
| Trailing PE | 8.95 |
| Forward PE | NM |
| P/S (TTM) | 1.16 |
| P/B | 1.05 |
| Price/FCF | 34 |
| EV/R | 1.66 |
| EV/Ebitda | 5.64 |
| PEG | 2.77 |
Amphastar P (AMPH) share price today is $18.18
Yes, Indians can buy shares of Amphastar P (AMPH) on Vested. To buy
Yes, you can purchase fractional shares of Amphastar P (AMPH) via the Vested app. You can start investing in Amphastar P (AMPH) with a minimum investment of $1.
You can invest in shares of Amphastar P (AMPH) via Vested in three simple steps:
The 52-week high price of Amphastar P (AMPH) is $31.26. The 52-week low price of Amphastar P (AMPH) is $17.03.
The price-to-earnings (P/E) ratio of Amphastar P (AMPH) is 8.9532
The price-to-book (P/B) ratio of Amphastar P (AMPH) is 1.05
The dividend yield of Amphastar P (AMPH) is 0.00%
The market capitalization of Amphastar P (AMPH) is $824.60M
The stock symbol (or ticker) of Amphastar P is AMPH
Consider the share price of Amphastar P as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Amphastar P has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Amphastar P shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Amphastar P stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Amphastar P and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Amphastar P stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
